1.
Cell Stem Cell
; 30(11): 1400-1402, 2023 11 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37922877
RESUMO
Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.